Giesel, Frederik L.
Kratochwil, Clemens
Schlittenhardt, Joel
Dendl, Katharina
Eiber, Matthias
Staudinger, Fabian
Kessler, Lukas
Fendler, Wolfgang P.
Lindner, Thomas
Koerber, Stefan A.
Cardinale, Jens
Sennung, David
Roehrich, Manuel
Debus, Juergen
Sathekge, Mike
Haberkorn, Uwe
Calais, Jeremie
Serfling, Sebastian
Buck, Andreas L.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 11 January 2021
Accepted: 8 March 2021
First Online: 17 June 2021
Declarations
:
: UH, TL, CK, and FLG have a patent application for quinolone based FAP-targeting agents for imaging and therapy in nuclear medicine. UH, TL, CK, and FLG also have shares of a consultancy group for iTheranostics. FLG is also advisor at ABX, Telix, and SOFIE Biosciences. JCa is supported by the Prostate Cancer Foundation (2020 Young Investigator Award 20YOUN05) and the Society of Nuclear Medicine and Molecular imaging (2019 ERF Molecular Imaging Research Grant for Junior Academic Faculty). The other authors declare no conflict of interest regarding this manuscript.